Relationship between short and long-term glycemic variability and oxidative stress in type 1 diabetes mellitus under daily life insulin treatment

ABSTRACT Objectives: The purpose of this study was to investigate the heterogeneity of the association between glycemic variability and oxidative stress markers in T1DM patients under daily life insulin treatment. Subjects and methods: We studied, in a cross-sectional analysis, 76 T1DM patients without clinical chronic diabetes complications and 22 healthy individuals. Were evaluated the short-term glycemic variability (STGV), long-term glycemic variability (LTGV), oxidative stress markers [8-isoprostaglandin-F2α (Ur-8-iso-PGF2α), nitric oxide (NO), thiobarbituric acid reactive substances (TBARS) and erythrocytes reduced/oxidized glutathione (GSH/GSSG)] and biochemical dosages (glycaemia, HbA1c, lipidogram, albuminuria). Results: Plasmatic NO was positively associated with LTGV (last year average of HbA1c) (8.7 ± 1.6% or 71 ± 18 mmol) (rS: 0.278; p: 0.042). Plasmatic TBARS, erythrocytes GSH/GSSH and Ur-8-iso-PGF-2α didn't show correlation with glycemic variability. GSH/GSSG was inversely correlated with LDL-cholesterol (rS: - 0.417; p: 0.047) and triglycerides (rS: −0.521; p: 0.013). Albuminuria was positive correlated with age (rS: 0.340; p: 0.002), plasmatic NO (rS: 0.267; p 0.049) and TBARS (rS: 0.327; p: 0.015). Conclusion: In daily life insulin treatment, young T1DM patients have higher plasmatic NO than healthy subjects. However, the correlation between glycemic variability and oxidative stress markers is heterogeneous. Lipid profile and albuminuria are associated with different oxidative stress markers. These data collaborate to explain the controversial results in this issue.

Suplementação proteica não aumenta a concentração plasmática de óxido nítrico em homens saudáveis / Protein supplementation does not increase nitric oxide plasmatic concentration in healthy men

Suplementos nutricionais, supostamente, capazes de potencializar a produção endógena de óxido nítrico (NO) têm experimentado crescente popularidade entre os indivíduos fisicamente ativos. Diante da carência de informações sobre o assunto, o objetivo do presente estudo foi avaliar o efeito de um suplemento comercial à base de proteínas e aminoácidos sobre a produção endógena de NO. MÉTODOS: A amostra foi constituída de 12 homens sedentários, mas sem fatores de risco para doenças cardiovasculares. O protocolo de suplementação foi conduzido conforme o arranjo experimental duplo-cego cruzado. Os participantes receberam, aleatoriamente, placebo (PLA) ou suplemento proteico (SP), em dois momentos diferentes, separados por uma semana. Com o intuito de determinar a concentração plasmática de NO, amostras de sangue foram coletadas antes (24h e imediatamente antes) e depois (30 e 60 minutos) do consumo da substância PLA ou do SP. RESULTADOS: Não foi observada alteração na concentração plasmática de NO após a ingestão do SP em comparação com o PLA (pós- suplementação 30min - PLA: 19,3 ± 4,7µmol.L- 1 vs. SP: 18,9 ± 4,4µmol.L-1 e pós-suplementação 60min - PLA: 21,3 ± 6,5µmol.L-1 vs. SP: 20,3 ± 4,9µmol.L-1). Também não foi verificada alteração da pressão arterial. CONCLUSÃO: O suplemento nutricional à base de proteínas e aminoácidos, testado no presente estudo, não potencializou a produção endógena de NO.

Nutritional supplements, theoretically able to increase endogenous nitric oxide (NO) production have experienced great popularity among physically active individuals. AIM: scientific evidence available regarding this issue is scarce. Therefore, the purpose of this study was to evaluate the effect of a dietary supplement commercialized as a nitric oxide booster. MATERIALS AND METHODS: twelve sedentary men with no risk factors for cardiovascular diseases were supplemented with placebo or protein in two different occasions. The present study was conducted in a cross double-blind design. In order to assess plasmatic NO concentration, blood samples were obtained before (24hs and immediately before) and after (30 and 60 minutes) consumption of placebo (PLA) or protein supplement (SP). RESULTS: there was no difference in plasmatic nitric oxide concentration between both trails (Post-supplementation 30 min - PLA: 19.3±4.7 µmol.L-1 vs. SP: 18.9±4.4 µmol.L-1 and Post-supplementation 60 min - PLA: 21.3±6.5 µmol.L-1 vs. SP: 20.3±4.9 µmol.L-1). In addition, no difference was detected for arterial blood pressure. CONCLUSION: the dietary supplement analyzed in the present study failed to increase nitric oxide endogenous production.